(19) World Intellectual Property **Organization**

International Bureau





(43) International Publication Date 20 January 2005 (20.01.2005)

PCT

(10) International Publication Number WO 2005/005668 A3

(51) International Patent Classification⁷:

C12Q 1/68

(21) International Application Number:

PCT/US2004/021944

(22) International Filing Date: 8 July 2004 (08.07.2004)

(25) Filing Language: English

English (26) Publication Language:

(30) Priority Data:

60/485,222 8 July 2003 (08.07.2003) US

(71) Applicant (for all designated States except US): OHIO UNIVERSITY [US/US]; Technology Transfer Office, 20 East Circle Drive, Athens, OH 45701 (US).

- (72) Inventors; and
- (75) Inventors/Applicants (for US only): KOPCHICK, John, J. [US/US]; 4 Orchard Lane, Athens, OH 45701 (US). RIDERS, Markus [US/US]; 602 W. Georgia, Gunnison, CO 81230 (US). COSCHIGANO, Karen, T. [US/US]; 11703 Channingway Blvd., The Plains, OH 45780 (US). GOSNEY, Elahu, S. [US/US]; 111 W. State Street, Athens, OH 45701 (US).
- (74) Agents: BROWDY AND NEIMARK, P.L.L.C. et al.; 624 Ninth Street N.W. ||Suite 300, Washington, DC 20001-5303 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of
- (88) Date of publication of the international search report: 9 September 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIAGNOSIS AND TREATMENT METHODS RELATED TO AGING (8A)

(57) Abstract: Mouse genes differentially expressed in comparisons of gene expression in growth hormone receptor/binding protein gene-disrupted mouse livers and normal mouse livers have been identified, as have corresponding human genes and proteins. The human molecules, or antagonists thereof, may be used for protection against faster-than-normal biological aging, or to achieve slower-than-normal biological aging. The human molecules may also be used as markers of biological aging, to retard biological aging, or to treat age-related diseases.



Intermenal Application No PCT/US2004/021944

A. CLASS	SIFICATION	OF SUB.	JECT M.	ATTER
TPC 7	C120	1/68		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\begin{tabular}{ll} \begin{tabular}{ll} Minimum documentation searched (classification system followed by classification symbols) \\ IPC 7 C12Q \\ \end{tabular}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, Sequence Search, EMBASE

	ENTS CONSIDERED TO BE RELEVANT	the character of	51 11 11 11
Category °	Citation of document, with indication, where appropriate, of t	the relevant passages	Relevant to claim No.
X	MERCHED A ET AL: "APOLIPOPRO CODON 360 MUTATION INCREASES AGING AND IS NOT ASSOCIATED WALZHEIMER'S DISEASE" NEUROSCIENCE LETTERS, LIMERIC vol. 242, no. 2, 13 February 1998 (1998-02-13) 117-119, XP000863724 ISSN: 0304-3940 the whole document	WITH HUMAN TITH K, IE,	1-3, 17-31
X Furth	ner documents are listed in the continuation of box C.	X Patent family members are listed i	n annex.
Special ca	tegories of cited documents :	"T" later document published after the inte	rnational filing date
 "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family	
filing d "L" docume which citation "O" docume other r	is cited to establish the publication date of another n or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or neans	cannot be considered to involve an induction document is combined with one or moments, such combination being obviouin the art.	ventive step when the ore other such docu- us to a person skilled
filing d 'L" docume which citation 'O" docume other r 'P" docume later th	is cited to establish the publication date of another n or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or neans	cannot be considered to involve an induction document is combined with one or moments, such combination being obviouin the art.	ventive step when the re other such docu- us to a person skilled
filing d "L" docume which citation "O" docume other r "P" docume later th	is cited to establish the publication date of another on or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filling date but han the priority date claimed	cannot be considered to involve an indocument is combined with one or moments, such combination being obviouin the art. "&" document member of the same patent	ventive step when the re other such docu- us to a person skilled

Interremal Application No
PCT/US2004/021944

- Declaration confidence	FC170320047021344		
	Deleventio (2.2. N		
ottation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
MICHIKAWA Y ET AL: "Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 286, 22 October 1999 (1999-10-22), pages 774-779, XP002179334 ISSN: 0036-8075 the whole document	1-3, 17-31		
LIO D ET AL: "Gender-specific association between -1082 IL-10 promoter polymorphism and longevity" GENES AND IMMUNITY, vol. 3, no. 1, February 2002 (2002-02), pages 30-33, XP008039832 ISSN: 1466-4879 the whole document	1-3, 17-31		
MOCCHEGIANI EUGENIO ET AL: "MTmRNA gene expression, via IL-6 and glucocorticoids, as potential genetic marker of immunosenescence: Lessons from very old mice and humans" EXPERIMENTAL GERONTOLOGY, vol. 37, no. 2-3, January 2002 (2002-01), pages 349-357, XP002312292 ISSN: 0531-5565 the whole document	1-3, 17-31		
WO 03/000861 A (LEHRER-GRAIWER JOSH; APFELD JAVIER (US); DILLIN ANDREW (US); GARIGAN) 3 January 2003 (2003-01-03) Methods to identify lifespan associated genes; gene therapy involving said genes the whole document	1-3, 17-31		
US 6 025 194 A (FUNK WALTER) 15 February 2000 (2000-02-15) GC6 gene as cell senescence marker gene the whole document/	1-3, 17-31		
	accumulation of point mutations in the human mtDNA control region for replication" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 286, 22 October 1999 (1999-10-22), pages 774-779, XP002179334 ISSN: 0036-8075 the whole document LIO D ET AL: "Gender-specific association between -1082 IL-10 promoter polymorphism and longevity" GENES AND IMMUNITY, vol. 3, no. 1, February 2002 (2002-02), pages 30-33, XP008039832 ISSN: 1466-4879 the whole document MOCCHEGIANI EUGENIO ET AL: "MTmRNA gene expression, via IL-6 and glucocorticoids, as potential genetic marker of immunosenescence: Lessons from very old mice and humans" EXPERIMENTAL GERONTOLOGY, vol. 37, no. 2-3, January 2002 (2002-01), pages 349-357, XP002312292 ISSN: 0531-5565 the whole document WO 03/000861 A (LEHRER-GRAIWER JOSH; APFELD JAVIER (US); DILLIN ANDREW (US); GARI GAN) 3 January 2003 (2003-01-03) Methods to identify lifespan associated genes; gene therapy involving said genes the whole document US 6 025 194 A (FUNK WALTER) 15 February 2000 (2000-02-15) GC6 gene as cell senescence marker gene the whole document		

Interranal Application No
PCT/US2004/021944

Category ° Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.	C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	10170320047021344
Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse)" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 94, no. 24, 25 November 1997 (1997-11-25), pages 13215-13220, XP002312293 ISSN: 0027-8424 The Laron or GHR/BP-deficient mouse is proposed as a useful animal model in the study of senescence	Category °		Relevant to claim No.
	A	Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse)" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 94, no. 24, 25 November 1997 (1997-11-25), pages 13215-13220, XP002312293 ISSN: 0027-8424 The Laron or GHR/BP-deficient mouse is proposed as a useful animal model in the study of senescence	

International application No. PCT/US2004/021944

INTERNATIONAL SEARCH REPORT

Box II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)				
This Inte	This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1. X	Claims Nos.: 4-16 (all completely), 17-31 (all partially) because they relate to subject matter not required to be searched by this Authority, namely: Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery				
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:				
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).				
Box III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)				
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:				
	see additional sheet				
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.				
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.				
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:				
4. X	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-30 (all partially), 31 (completely)				
Remark	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.				

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-30 (all partially), 31 (completely)

Invention 1: methods of determining a biological age, or rate of biological aging, or reducing a rate of biological aging, and/or delying the time of onset, or reducing the severity, of an undesirable age-related phenotype, and/or protecting against an age-related disease in a human subject, using clone 4-11

2. claims: 1-30 (all partially), 32 (completely)

Invention 2: methods of determining a biological age, or rate of biological aging, or reducing a rate of biological aging, and/or delying the time of onset, or reducing the severity, of an undesirable age-related phenotype, and/or protecting against an age-related disease in a human subject, using clone 4-29

3. claims: 1-30 (all partially), 33 (completely)

Invention 3: methods of determining a biological age, or rate of biological aging, or reducing a rate of biological aging, and/or delying the time of onset, or reducing the severity, of an undesirable age-related phenotype, and/or protecting against an age-related disease in a human subject, using clone 4-97

4. claims: 1-30 (all partially), 34 (completely)

Invention 4: methods of determining a biological age, or rate of biological aging, or reducing a rate of biological aging, and/or delying the time of onset, or reducing the severity, of an undesirable age-related phenotype, and/or protecting against an age-related disease in a human subject, using clone 4-130

5. claims: 1-30 (all partially), 35 (completely)

Invention 5: methods of determining a biological age, or rate of biological aging, or reducing a rate of biological aging, and/or delying the time of onset, or reducing the severity, of an undesirable age-related phenotype, and/or protecting against an age-related disease in a human subject, using clone 5-105

6. claims: 1-30 (all partially), 36 (completely)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Invention 6: methods of determining a biological age, or rate of biological aging, or reducing a rate of biological aging, and/or delying the time of onset, or reducing the severity, of an undesirable age-related phenotype, and/or protecting against an age-related disease in a human subject, using clone 5-38

7. claims: 1-30 (all partially), 37 (completely)

Invention 7: methods of determining a biological age, or rate of biological aging, or reducing a rate of biological aging, and/or delying the time of onset, or reducing the severity, of an undesirable age-related phenotype, and/or protecting against an age-related disease in a human subject, using clone 5-41

8. claims: 1-30 (all partially), 38 (completely)

Invention 8: methods of determining a biological age, or rate of biological aging, or reducing a rate of biological aging, and/or delying the time of onset, or reducing the severity, of an undesirable age-related phenotype, and/or protecting against an age-related disease in a human subject, using clone 5-43

9. claims: 1-30 (all partially), 39 (completely)

Invention 9: methods of determining a biological age, or rate of biological aging, or reducing a rate of biological aging, and/or delying the time of onset, or reducing the severity, of an undesirable age-related phenotype, and/or protecting against an age-related disease in a human subject, using clone 5-61

10. claims: 1-30 (all partially), 40 (completely)

Invention 10: methods of determining a biological age, or rate of biological aging, or reducing a rate of biological aging, and/or delying the time of onset, or reducing the severity, of an undesirable age-related phenotype, and/or protecting against an age-related disease in a human subject, using clone 5-9

11. claims: 1-30 (all partially), 41 (completely)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Invention 11: methods of determining a biological age, or rate of biological aging, or reducing a rate of biological aging, and/or delying the time of onset, or reducing the severity, of an undesirable age-related phenotype, and/or protecting against an age-related disease in a human subject, using clone 5-138

information on patent family members

Internation No
PCT/US2004/021944

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 03000861	Α	03-01-2003	CA EP WO US	2451247 A1 1406489 A2 03000861 A2 2003190312 A1	
US 6025194	Α	15-02-2000	AU WO	1701599 A 9925878 A2	07-06-1999 27-05-1999